RFP - Filgrastim Syringes or Biosimilar
Open Solicitation Posted
- Solicitation number
- 36E79727R0001
- Agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The VA National Acquisition Center seeks offers for Filgrastim syringes in 300MCG (non-safety) or biosimilar and 480MCG (non-safety) or biosimilar formulations, with proposals due December 9, 2026 at 2:30 PM CST. The Set Aside line reads "No Set-Aside Used," and the notice states no sole-source intent or contract vehicle requirement. The attachment summary attributes issuance to the VA Enterprise Procurement Office, and the solicitation is issued under SF-1449 for commercial products and services. The NAICS code is 325412, Pharmaceutical Preparation Manufacturing, and the PSC is 6505, Drugs and Biologicals.
Estimated annual requirements are 22,665 syringes for the 300MCG line and 29,170 for the 480MCG line. Award will be made in the aggregate for both line items. The contract includes an implementation period of a maximum of 60 days or until June 29, 2027, followed by a one-year base ordering period and four optional one-year periods. Prices are required for the base year and all four option years, limited to two decimal places, and must include a 0.5% Cost Recovery Fee.
Government participants include all VA facilities, Department of Defense ordering activities, Indian Health Service facilities, Bureau of Prisons, Captain James A. Lovell Federal Health Care Center, and Option 2 State Veteran Homes. Products are distributed through Pharmaceutical Prime Vendor programs, with the VA PPV managed by McKesson Corporation and DoD PPVs managed by McKesson, Cencora, Cardinal Health, and DMS Pharmaceutical Group.
Offerors must provide a unique 11-digit NDC for each product, make all commercial package sizes available, and furnish FDA approval documentation confirming acceptable current Good Manufacturing Practices (cGMP) status for all manufacturing facilities. Distributors must submit Letters of Commitment from manufacturers. Products must comply with the Drug Supply Chain Security Act, including serialized transaction information using GS1 EPCIS standards and registration in the National Association of Boards of Pharmacy Trading Partner Directory. Covered drugs must meet Federal Ceiling Price limitations under 38 U.S.C. 8126. The contractor must maintain the same manufacturer and NDA/ANDA/BLA for the duration unless the Contracting Officer approves changes.
The attachments include a Small Business Subcontracting Plan template (08/2026) under FAR 52.219-9(d), with goal categories for SB, VOSB, SDVOSB, SDB, WOSB, and HUB.
Proposals must be submitted in Microsoft Word or PDF format by email to Dov Vysnia (dov.vysnia@va.gov) and Teresa Hussain (teresa.hussain@va.gov), with a scanned signed SF-1449. Faxed proposals will be rejected.
Notice text
See attached documents.
Files
| File | Type | Posted |
|---|---|---|
| SubcontractingPlan_Template_08_2026.pdf | ||
| 36E79727R0001.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Filgrastim Biosimilar (VA-27-00012533) | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Vancomycin hydrochlor and 1 more item | Medical Supply Chain | No set-aside | |
| Syringe and needle, HY | Medical Supply Chain | No set-aside | |
| Syringe, hypodermic | Medical Supply Chain | No set-aside | |
| 6505--VA Loma Linda FDG | Veterans Integrated Service Network 22 | No set-aside | |
| 6505--Nitroglycerin SL Tablets (VA-27-00011802) | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity